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Biosketch 
Paola Carrai, MD is a liver transplant hepatologist. She graduated from the University of Pisa and 
completed her post-graduate residency program in  Internal Medicine at the same University. 
During the last 15 years, Dr. Carrai has been serving as transplant hepatologist for pre- and post-
transplant patients and has accumulated wide experience in the treatment of liver decompensation 
in waitlist patients, immunosuppressive therapy, and viral treatment of hepatitis C and B virus 
infection pre- and post-transplant.   
 
Abstract 
We report a case of post-transplant liver graft infection with Schistosoma spp in a migrant from 
Sub-Saharan Africa transplanted for HBV-related cirrhosis with pre-transplant undiagnosed 
schistosomiasis. The emergence of tropical diseases in non-endemic areas warrant screening 
protocols for donors and recipients with exposure in endemic areas. 
 
Text 
Schistosomiasis is a chronic parasitic disease affecting 230 million people worldwide [1]. The 
infection occurs largely in sub-Saharan Africa (SSA) with a prevalence between10 and ≥50% [2]. In 
non-endemic areas like Italy, prevalence rates between 7 and 34% are reported in migrants from 
SSA [3, 4]. The infection is acquired when free-swimming cercariae penetrate the skin of people 
exposed to infested freshwater [1]. After penetrating the skin, the parasites migrate through the 
venous and general circulation, and finally concentrate in mesenteric or bladder veins, where they 
present in the form of male-female couples. Adult Schistosomas usually  live up to 3–10 years, but 
parasites surviving for 40 years have been reported [1]. Adult females produce hundreds to 
thousands of eggs daily. These in turn may be eliminated with urine or feces, or become trapped in 
nearby tissues where they induce a local granulomatous inflammation and fibrosis leading to tissue 
damage [1]. SSA is endemic for four Schistosoma species. Schistosoma mansoni and S. 
haematobium are widespread in the African continent, whereas S. intercalatum and S. guineensis 
are less common and restricted to West and Central Africa [1, 5]. In the early phases, 
schistosomiasis may be completely asymptomatic, while hepatic, intestinal, and genito-urinary 
complications have been reported in chronic patients [2]. Herein we report a case of post 
transplant liver graft infection with Schistosoma spp in a patient from SSA. 
 
The study 
In July 2016, a 20-year-old male migrant from Liberia was admitted to our Unit for decompensated 
hepatitis B virus (HBV)-related cirrhosis. The patient had arrived in Italy 1 month earlier after a 3-
month stay in Libya and a 4-month stay in Algeria. His previous clinical history was unremarkable. 
On admission, his blood tests showed slight leucopenia without eosinophilia; thrombocytopenia 
(platelet 63,000/µL); total bilirubin 33.86 mg/dL; AST 99U/L; ALT 39 U/L; alkaline phosphatase 167 
U/L; albumin 3 g/dL; INR 2.41, and serum creatinine 0.85 mg/dL. His model for end-stage liver 
disease (MELD) score was 31. The viral serology was positive for HBV surface antigen (HBsAg), 
antibody to HBV core antigen (anti-HBc-IgG), and antibody to hepatitis delta virus (anti-HDV). 
HBV-DNA was 1.6 log. The abdominal CT scan showed marked splenomegaly (26 cm) and mild 
ascites. The esophagogastroduodenoscopy revealed F1 esophageal varices.  
 Treatment with entecavir 0.5 mg was started, and the patient underwent liver transplantation from 
an Italian deceased donor. The routine pre-transplant screening for infectious disease was 
unremarkable, showing previous EBV, CMV and Toxoplasma gondii infections. Histology of the 
native liver confirmed the diagnosis of HBV-related macronodular cirrhosis. Post-transplantation, 
the patient was started on quadruple immunosuppression with anti-CD25 (basiliximab, SimulectTM, 
Novartis Italy, Origgio (VA)); tacrolimus (PrografTM, Astellas, Assago (MI)) adjusted to a target 
trough level of 8-10 ng/mL; mycophenolate mofetil 500 mg b.i.d., and steroids from the anhepatic 
phase and tapered to 25 mg/day from day 7. Treatment with entecavir was continued and 
combined with anti-HBs immunoglobulin.  
 
Two months after transplantation, the routine follow-up exams showed a 5-fold increase in 
transaminases without evidence of viral reactivation and partially responsive to increase of 
immunosuppression. Due to persistent increase in his liver function tests, the patient underwent 
liver biopsy 6 months post-transplantation. Histology showed inflammatory infiltration suggestive of 
mild acute cellular rejection and the presence of an oval structure with a terminal spine inside an 
eosinophilic granuloma (Figure 1), and consistent with Schistosoma spp egg. The serology for 
Schistosoma spp (Schisto II Western blot IgG, LDBIO Diagnostics, Lyon, France) and the urinary 
immunocromatographic test for circulating cathodic antigen (ICT-CCA, NADAL CCA Bilharzia test, 
Germany) tested positive, while parasitological examination of stool and urine (3 samples each) 
was negative.  
Eight months post-transplantation, the patient was started on praziquantel (40 mg/kg/day in two 
split doses on two separate days three weeks apart) and followed by ICT-CCA negativity and 
normal transaminases 2 weeks later. Strongyloides stercoralis Agar plate stool culture and 
antibodies were both negative. Retrospective examination of the recipient’s native liver was 
negative for hepatic schistosomiasis, while the donor was born in Italy without history of travels in 
endemic areas for schistosomiasis.  
 
Conclusions 
Recent migration from SSA is driving an increase in cases of reported schistosomiasis and other 
neglected tropical diseases in Southern Europe [4, 6], and evidence of local autochthonous 
transmission of Schistosoma in Europe is also available [7]. Along with other parasitic infections, 
such as Chagas disease and strongyloidiasis, schistosomiasis may have several implications for 
solid organ transplant patients. Hepatic schistosomiasis due to S. mansoni and S. japonicum may 
lead to progressive fibrosis and portal hypertension [8]. Even though the hepatocellular function is 
preserved until the late stage of the disease, may be necessary in the end-stage disease [8]. In a 
transplant center in Saudi Arabia, S. mansoni was indication to liver transplantation for 3% of 
patients undergoing liver transplantation [8]. In patients with S. haematobium infection, renal 
impairment is primarily caused by obstruction, reflux and stone formation related to fibrosis and 
calcification of tissue-trapped ova in the lower urinary tract [9]. Amyloidosis and glomerulonephritis 
may develop in S. haematobium or S. mansoni infection as a consequence of immune complexes 
containing worm antigens and deposited in the glomeruli [9]. In Egypt, schistosomiasis accounts 
for 10% of chronic renal failure and ranks second after diabetes mellitus [10]. If appropriately 
treated before transplantation, patients with schistosomiasis undergoing kidney or liver 
transplantation have outcomes comparable to other indications [8, 11]. However, renal transplant 
recipients with schistosomiasis are reported to require higher dose of cyclosporine with subsequent 
higher incidence of nephrotoxicity, urinary tract infections and complications [11]. 
Experiences from endemic suggests that uncomplicated infection is not a contraindication to organ 
donation. In endemic areas, living donors should be screened for schistosomiasis and infected 
donors be treated with praziquantel before donation [12, 13]. Transmission of living Schistosoma 
worms through the graft seems unlikely, since adult worms live in mesenteric and bladder veins, 
while granulomas containing eggs may be found in kidneys and liver [12]. This is why, due to 
praziquantel being active mainly against adult worms, the efficacy for patients receiving 
Schistosoma-infected grafts is largely debated [12]. Successful use of Schistosoma-infected liver 
grafts [12] has been reported, as well as kidney transplantation  from donors with schistosomiasis 
[11]. 
The present case is consistent with graft infection from eggs produced by adult worms harbored by 
the recipient well before transplantation, rather than with donor-to-recipient transmission. The 
shape of the eggs was consistent with S. haematobium or its hybrid with other species (e.i. S. 
bovis, S. guineensis or S. curassoni based on the country of origin the shape and size of the 
terminal spine (M. Albonico, personal communication). The occurrence of schistosomiasis in non-
endemic areas warrant implementation of screening protocols for donors and recipients with a 
history positive for exposure in endemic areas, including other parasitic disease such as 
strongyloidiasis [14]
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Figure 1: Liver biopsy six months after transplantation (HxE). Histology showed mild acute cellular 
rejection and an eosinophilic granuloma containing an ovum provided with a terminal spine, 
consistent with Schistosoma. A) Original magnification 200x, B) Original magnification 400x; C)  
Original magnification 1000x.  
 
